National Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad, Palaj (An Institute of National Importance), Opposite Air Force Station, Gandhinagar 382355, Gujarat, India.
Mol Pharm. 2021 Feb 1;18(2):641-666. doi: 10.1021/acs.molpharmaceut.0c00094. Epub 2020 May 26.
Diabetic nephropathy (DN), a chronic progressive kidney disease, is a significant complication of diabetes mellitus. Dysregulation of the histone deacetylases (HDACs) gene has been implicated in the pathogenesis of DN. Hence, the HDAC-inhibitors have emerged as a critical class of therapeutic agents in DN; however, the currently available HDAC4-inhibitors are mostly nonselective in nature as well as inhibit multiple HDACs. RNA interference of HDAC4 (HDAC4 siRNA) has shown immense promise, but the clinical translation has been impeded due to lack of a targeted, specific, and applicable delivery modality. In the present investigation, we examined Cyclo(RGDfC) (cRGD) truncated polymeric nanoplex with dendrimeric templates for targeted HDAC4 Gene Silencing. The developed nanoplex exhibited enhanced encapsulation of siRNA and offered superior protection against serum RNase nucleases degradation. The nanoplex was tested on podocytes (), wherein it showed selective binding to the αvβ3 integrin receptor, active cellular uptake, and significant gene silencing. The experiments showed remarkable suppression of the HDAC4 and inhibition in the progression of renal fibrosis in the Streptozotocin (STZ) induced DN C57BL/6 mice model. Histopathological and toxicological studies revealed nonsignificant abnormality/toxicity with the nanoplex. Conclusively, nanoplex was found as a promising tactic for targeted therapy of podocytes and could be extended for other kidney-related ailments.
糖尿病肾病(DN)是一种慢性进行性肾病,是糖尿病的严重并发症。组蛋白去乙酰化酶(HDACs)基因的失调与 DN 的发病机制有关。因此,HDAC 抑制剂已成为 DN 治疗的重要药物类别;然而,目前可用的 HDAC4 抑制剂在性质上大多是非选择性的,并抑制多种 HDACs。HDAC4 的 RNA 干扰(HDAC4 siRNA)显示出巨大的潜力,但由于缺乏靶向、特异和适用的传递方式,其临床转化受到阻碍。在本研究中,我们研究了具有树状模板的 Cyclo(RGDfC)(cRGD)截断聚合物纳米复合物,用于靶向 HDAC4 基因沉默。开发的纳米复合物表现出增强的 siRNA 包封,并提供了对血清 RNase 核酸酶降解的卓越保护。该纳米复合物在足细胞()上进行了测试,结果表明它选择性地与αvβ3 整联蛋白受体结合,具有主动的细胞摄取能力,并能显著进行基因沉默。实验表明,该纳米复合物可显著抑制 STZ 诱导的 DN C57BL/6 小鼠模型中的 HDAC4 并抑制肾纤维化的进展。组织病理学和毒理学研究显示纳米复合物无明显异常/毒性。总之,纳米复合物被发现是一种针对足细胞的有前途的靶向治疗策略,并可扩展用于治疗其他肾脏相关疾病。